Early-Stage trial for tough childhood cancers halted
NCT ID NCT05429502
Summary
This study aimed to test the safety and find the right dose of a three-drug combination (ribociclib, topotecan, and temozolomide) for children and young adults whose cancers had returned or did not respond to standard treatments. It focused on aggressive cancers like neuroblastoma and certain brain tumors. The trial was terminated early, so only the initial safety and dosing phase was completed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cohen Children's Medical Center of New York
New Hyde Park, New York, 11040, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Novartis Investigative Site
Cologne, 50937, Germany
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Sutton, Surrey, SM2 5PT, United Kingdom
-
St Jude s Childrens Research Hospital
Memphis, Tennessee, 38105-2794, United States
Conditions
Explore the condition pages connected to this study.